ProQR Therapeutics N.V. Begins Enrollment for PQ-010-001 Study

ProQR Therapeutics N.V.(PRQR) says enrollment has started in study PQ-010-001, a global Phase 1b clinical study of QR-010, an investigational RNA therapeutic designed to repair the genetic mutation in the mRNA of cystic fibrosis (CF) patients due to the DF508 mutation.